[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332272-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332272-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","metformin-use-and-survival-in-people-with-ovarian-cancer-a-population-based-cohort-study-from-british-columbia-canada","Metformin use and survival in people with ovarian cancer - A population-based cohort study from British Columbia, Canada","","There is ongoing debate about whether metformin improves survival for people with ovarian cancer. A population-based cohort study used methods designed to avoid immortal time bias by applying time-dependent analyses to all 4,951 patients diagnosed between 1997 and 2018 in British Columbia, Canada. Cox proportional hazards models estimated survival associations in the overall cohort and among patients with diabetes. Metformin showed non-significant benefit in the full cohort but a significant protective effect in the diabetic subgroup.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/metformin-use-and-survival-in-people-with-ovarian-cancer-a-population-based-cohort-study-from-british-columbia-canada/332272/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/metformin-use-and-survival-in-people-with-ovarian-cancer-a-population-based-cohort-study-from-british-columbia-canada/332272.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about metformin and ovarian cancer?","Question",{"text":63,"@type":64},"The study examines whether metformin use is associated with improved survival in people with ovarian cancer, addressing an active debate in the field.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study reduce immortal time bias?",{"text":68,"@type":64},"It used time-dependent analyses, so metformin exposure and outcomes could be evaluated in a way that prevents participants from being unable to experience the outcome during an early study interval.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main survival results, especially for the diabetic subgroup?",{"text":72,"@type":64},"In the full cohort, metformin use was associated with better survival but not statistically significant. When restricted to patients with diabetes, metformin showed a statistically significant protective effect, which was also observed among serous cancer patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332272,1790014828,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":106,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Neoplasia 56 (2024) 101026  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>Metformin use and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada |  |  | |\n| --- | --- | --- | --- |\n| Paramdeep Kaura , Andrew Berchuck b , Anne Chase c , Bronwyn Groutd ,\u003Cbr>Cindy McKinnon Deurlooe , Leigh C. Pearce f, Malcolm C. Pike g, h , Jean Richardson h , Kathryn L. Terry i,j , Penelope M. Webb k , Gillian E. Hanley a, *\u003Cbr>a Department of Gynaecology and Obstetrics, Division of Gynaecologic Oncology, University of British Columbia, Vancouver, Canada b Department of Gynecologic Oncology, Duke University Medical Center, Durham, NC, United States\u003Cbr>c Regina, SK, Canada\u003Cbr>d Patient advocate, Sydney, NSW, Australia e Patient advocate, East Hampstead, NH, United States\u003Cbr>f Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, United States g Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States h Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States\u003Cbr>i Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, United States\u003Cbr>j Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, United States k Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords: Metformin Ovarian cancer Immortal time bias Survival |  | Objectives: There is an active debate regarding whether metformin use improves survival in people with ovarian cancer. We examined this issue using methods designed to avoid immortal time bias—as bias that occurs when participants in a study cannot experience the outcome for a certain portion of the study time.\u003Cbr>Methods: We used time-dependent analyses to study the association between metformin use for all 4,951 patients diagnosed with ovarian cancer in 1997 through 2018 in the province of British Columbia, Canada. Cox proportional hazards models were run to estimate the association between metformin and survival in the full cohort of ovarian cancer patients and among a cohort restricted to patients with diabetes.\u003Cbr>Results: Metformin use was associated with a 17 % better ovarian cancer survival in the full cohort (adjusted hazard ratio (aHR) = 0.83 (95 %CI 0.67, 1.02)), and a 16 % better ovarian cancer survival for serous cancers patient’s cohort (aHR = 0.84 (95 %CI 0.66, 1.07)), although both were not significant. However, a statistically significant protective effect was observed when restricting to the diabetic cohort (aHR = 0.71 (95 %CI 0.54–0.91)), which was also seen among serous cancers (aHR = 0.73 (95 %CI 0.54–0.98)).\u003Cbr>Conclusion: Metformin use was associated with improved ovarian cancer survival. The lack of statistical significance in the full cohort may reflect that diabetes is associated with reduced cancer survival, and thus diabetes itself may offset the benefit of metformin when examining the full cohort. Future research should examine metformin use among non-diabetic ovarian cancer patients. |  |\n\nIntroduction  \nOvarian cancer is the fifth most common cause of cancer deaths among females in developed countries. There is still no effective screening method for ovarian cancer [1], and most people are diagnosed in late stages with 5-year survival rates of 15–30 %.[2,3].  \nMetformin, a member of the biguanide class of drugs, is widely used  \nas first-line therapy for type 2 diabetes to normalize hyperglycemia [4]. Epidemiologic studies have reported that metformin use is associated with a reduced risk of cancer in diabetic patients, including a reduced incidence of","cbCaiqvPRGSArDir","https://ap.wps.com/l/cbCaiqvPRGSArDir","pdf",546384,"English","# Introduction\n## Study rationale and background\n# Methods\n## Study design and statistical analysis\n# Results\n## Full cohort findings\n## Diabetes and serous cancer subgroup findings\n# Conclusion\n## Interpretation and future research directions","[{\"question\":\"What question does the study address about metformin and ovarian cancer?\",\"answer\":\"The study examines whether metformin use is associated with improved survival in people with ovarian cancer, addressing an active debate in the field.\"},{\"question\":\"How did the study reduce immortal time bias?\",\"answer\":\"It used time-dependent analyses, so metformin exposure and outcomes could be evaluated in a way that prevents participants from being unable to experience the outcome during an early study interval.\"},{\"question\":\"What were the main survival results, especially for the diabetic subgroup?\",\"answer\":\"In the full cohort, metformin use was associated with better survival but not statistically significant. When restricted to patients with diabetes, metformin showed a statistically significant protective effect, which was also observed among serous cancer patients.\"}]","Metformin use and survival in people with ovarian cancer - A population-based cohort study from British Columbia, Canada | PDF",1789997615,18]